

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2 (b)

Enzon Pharmaceuticals, Inc.

-----  
(Name of Issuer)

Common Stock

-----  
(Title of Class of Securities)

293904108

-----  
(CUSIP Number)

August 9, 2006

-----  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule  
is filed:

Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's  
initial filing on this form with respect to the subject class of securities, and  
for any subsequent amendment containing information which would alter  
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed  
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of  
1934 ("Act") or otherwise subject to the liabilities of that section of the Act  
but shall be subject to all other provisions of the Act (however, see the  
Notes).

CUSIP No. 293904108

13G

Page 2 of 8 Pages

-----  
1. NAMES OR REPORTING PERSONS  
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

Renaissance Technologies Corp. 13-3127734

-----  
2. CHECK APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

(a)   
(b)

-----  
3. SEC USE ONLY

-----  
4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

-----  
5. SOLE VOTING POWER

3,445,884

-----  
NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING

6. SHARED VOTING POWER

0

-----  
7. SOLE DISPOSITIVE POWER

PERSON 3,445,884  
WITH -----  
8. SHARED DISPOSITIVE POWER  
0

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
3,445,884

10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
(SEE INSTRUCTIONS) |\_ |

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
7.85%

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
IA

1. NAMES OR REPORTING PERSONS  
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS  
James H. Simons

2. CHECK APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):  
(a) |\_ |  
(b) |\_ |

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION  
United States

5. SOLE VOTING POWER  
3,445,884

NUMBER OF 6. SHARED VOTING POWER  
SHARES 0  
BENEFICIALLY

OWNED BY 7. SOLE DISPOSITIVE POWER  
EACH 3,445,884  
REPORTING

PERSON 8. SHARED DISPOSITIVE POWER  
WITH 0

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
3,445,884

10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
(SEE INSTRUCTIONS) |\_ |

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
7.85%

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CUSIP No. 293904108

13G

Page 4 of 8 Pages

## Item 1.

- (a) Name of Issuer.

Enzon Pharmaceuticals, Inc

- (b) Address of Issuer's Principal Executive Offices.

685 Route 202/206  
Bridgewater, NJ 08807

## Item 2.

- (a) Name of Person Filing.

This Schedule 13G is being filed by Renaissance Technologies Corp.  
("RTC") and James H. Simons ("Simons").

- (b) Address of Principal Business Office or, if none, Residence.

The principal business address of the reporting persons is:

800 Third Avenue  
New York, New York 10022

- (c) Citizenship.

Dr. Simons is a United States citizen and  
RTC is a Delaware corporation

- (d) Title of Class of Securities.

Common Stock

- (e) CUSIP Number.

293904108

Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c),  
check whether the person filing is a:

- (a)  Broker or dealer registered under Section 15 of the Act.  
(b)  Bank as defined in Section 3(a)(6) of the Act.  
(c)  Insurance Company as defined in Section 3(a)(19) of the Act.  
(d)  Investment Company registered under Section 8 of the Investment  
Company Act.  
(e)  Investment Adviser in accordance with Sec.  
240.13d-1(b)(1)(ii)(E).  
(f)  Employee Benefit Plan or Endowment Fund in accordance with Sec.  
240.13d1(b)(1)(ii)(F).  
(g)  Parent holding company, in accordance with Sec.  
240.13d-1(b)(ii)(G).  
(h)  A savings association as defined in Section 3(b) of the Federal  
Deposit Insurance Act.  
(i)  A church plan that is excluded from the definition of an  
investment company under Section 3(c)(14) of the Investment  
Company Act of 1940.  
(j)  Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Sec. 240.13d-1(c), check this box

Item 4. Ownership

(a) Amount Beneficially Owned.

RTC: 3,445,884 shares

Simons: 3,445,884 shares, comprising the shares beneficially owned by RTC, because of Dr. Simons' position as control person of RTC.

(b) Percent of Class. RTC: 7.85%  
Simons: 7.85%

(c) Number of shares as to which each such person has

(i) sole power to vote or to direct the vote: RTC: 3,445,884  
Simons: 3,445,884

(ii) shared power to vote or to direct the vote: 0

(iii) sole power to dispose or to direct the disposition of: RTC: 3,445,884  
Simons: 3,445,884

(iv) shared power to dispose or to direct the disposition of: 0

Page 5 of 8 Pages

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Certain funds and accounts managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report. RIEF Trading LLC holds of record more than 5% of such securities.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Page 6 of 8 Pages

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I

certify that the information set forth in this statement is true, complete and correct.

Date: February 12, 2007

/s/ James H. Simons

-----  
James H. Simons

Renaissance Technologies Corp.

By: /s/ Mark Silber

-----  
Mark Silber  
Vice President

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

EXHIBIT 99.1

AGREEMENT REGARDING JOINT FILING UNDER  
UNDER RULE 13D-1(K) OF THE EXCHANGE ACT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of Common Stock of Enzon Pharmaceuticals, Inc.

Date: February 12, 2007

/s/ James H. Simons

-----  
James H. Simons

Renaissance Technologies Corp.

By: /s/ Mark Silber

-----  
Mark Silber  
Vice President